Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
about
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.Unmet needs in the first-line treatment of follicular lymphoma.
P2860
Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Frontline rituximab monotherap ...... A cost-effectiveness analysis.
@en
type
label
Frontline rituximab monotherap ...... A cost-effectiveness analysis.
@en
prefLabel
Frontline rituximab monotherap ...... A cost-effectiveness analysis.
@en
P2093
P2860
P356
P1433
P1476
Frontline rituximab monotherap ...... A cost-effectiveness analysis.
@en
P2093
Anca Prica
Kelvin Chan
Matthew Cheung
P2860
P304
P356
10.1002/CNCR.29372
P407
P577
2015-04-15T00:00:00Z